141 related articles for article (PubMed ID: 17230522)
1. Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
Edwards CM; Mueller G; Roelofs AJ; Chantry A; Perry M; Russell RG; Van Camp B; Guyon-Gellin Y; Niesor EJ; Bentzen CL; Vanderkerken K; Croucher PI
Int J Cancer; 2007 Apr; 120(8):1657-63. PubMed ID: 17230522
[TBL] [Abstract][Full Text] [Related]
2. Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth.
Moriceau G; Roelofs AJ; Brion R; Redini F; Ebetion FH; Rogers MJ; Heymann D
Cancer; 2012 Feb; 118(3):750-60. PubMed ID: 21751201
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
Croucher PI; De Hendrik R; Perry MJ; Hijzen A; Shipman CM; Lippitt J; Green J; Van Marck E; Van Camp B; Vanderkerken K
J Bone Miner Res; 2003 Mar; 18(3):482-92. PubMed ID: 12619933
[TBL] [Abstract][Full Text] [Related]
4. Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Roelofs AJ; Edwards CM; Russell RG; Ebetino FH; Rogers MJ; Hulley PA
J Pharmacol Exp Ther; 2007 Jul; 322(1):228-35. PubMed ID: 17412884
[TBL] [Abstract][Full Text] [Related]
5. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.
Vanderkerken K; Medicherla S; Coulton L; De Raeve H; Willems A; Lawson M; Van Camp B; Protter AA; Higgins LS; Menu E; Croucher PI
Cancer Res; 2007 May; 67(10):4572-7. PubMed ID: 17495322
[TBL] [Abstract][Full Text] [Related]
7. The mevalonate/isoprenoid pathway inhibitor apomine (SR-45023A) is antiproliferative and induces apoptosis similar to farnesol.
Flach J; Antoni I; Villemin P; Bentzen CL; Niesor EJ
Biochem Biophys Res Commun; 2000 Apr; 270(1):240-6. PubMed ID: 10733934
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
[TBL] [Abstract][Full Text] [Related]
9. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity.
Staal A; Frith JC; French MH; Swartz J; Güngör T; Harrity TW; Tamasi J; Rogers MJ; Feyen JH
J Bone Miner Res; 2003 Jan; 18(1):88-96. PubMed ID: 12510809
[TBL] [Abstract][Full Text] [Related]
10. Geranylgeranyl transferase type II inhibition prevents myeloma bone disease.
Lawson MA; Coulton L; Ebetino FH; Vanderkerken K; Croucher PI
Biochem Biophys Res Commun; 2008 Dec; 377(2):453-457. PubMed ID: 18929536
[TBL] [Abstract][Full Text] [Related]
11. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
Shipman CM; Croucher PI; Russell RG; Helfrich MH; Rogers MJ
Cancer Res; 1998 Dec; 58(23):5294-7. PubMed ID: 9850051
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
Croucher PI; Shipman CM; Van Camp B; Vanderkerken K
Cancer; 2003 Feb; 97(3 Suppl):818-24. PubMed ID: 12548581
[TBL] [Abstract][Full Text] [Related]
13. The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
Martin SK; Gan ZY; Fitter S; To LB; Zannettino AC
Leuk Res; 2015 Mar; 39(3):380-7. PubMed ID: 25624048
[TBL] [Abstract][Full Text] [Related]
14. Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.
Buckle CH; De Leenheer E; Lawson MA; Yong K; Rabin N; Perry M; Vanderkerken K; Croucher PI
PLoS One; 2012; 7(8):e41127. PubMed ID: 22952578
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis.
Hussein O; Tiedemann K; Komarova SV
Bone; 2011 Feb; 48(2):202-11. PubMed ID: 20849994
[TBL] [Abstract][Full Text] [Related]
16. Apomine, a novel hypocholesterolemic agent, accelerates degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and stimulates low density lipoprotein receptor activity.
Roitelman J; Masson D; Avner R; Ammon-Zufferey C; Perez A; Guyon-Gellin Y; Bentzen CL; Niesor EJ
J Biol Chem; 2004 Feb; 279(8):6465-73. PubMed ID: 14627708
[TBL] [Abstract][Full Text] [Related]
17. Compactin suppresses bone resorption by inhibiting the fusion of prefusion osteoclasts and disrupting the actin ring in osteoclasts.
Woo JT; Kasai S; Stern PH; Nagai K
J Bone Miner Res; 2000 Apr; 15(4):650-62. PubMed ID: 10780857
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo.
Hughes DE; Wright KR; Uy HL; Sasaki A; Yoneda T; Roodman GD; Mundy GR; Boyce BF
J Bone Miner Res; 1995 Oct; 10(10):1478-87. PubMed ID: 8686503
[TBL] [Abstract][Full Text] [Related]
19. The backbone of progress--preclinical studies and innovations with zoledronic acid.
Green JR; Guenther A
Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S3-S12. PubMed ID: 21353178
[TBL] [Abstract][Full Text] [Related]
20. Induction of apoptosis in breast cancer cells by apomine is mediated by caspase and p38 mitogen activated protein kinase activation.
Lowe LC; Senaratne SG; Colston KW
Biochem Biophys Res Commun; 2005 Apr; 329(2):772-9. PubMed ID: 15737653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]